Liu Y, Tao H, Jia S, Wang H, Guo L, Hu Z
Mol Clin Oncol. 2025; 22(2):19.
PMID: 39776943
PMC: 11706340.
DOI: 10.3892/mco.2024.2814.
Derangula S, Nadumane V
Cell Biochem Biophys. 2024; 82(2):1061-1077.
PMID: 38578403
DOI: 10.1007/s12013-024-01258-0.
Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M
Ther Adv Med Oncol. 2023; 15:17588359231205848.
PMID: 37841752
PMC: 10571689.
DOI: 10.1177/17588359231205848.
Huang L, Zhang A, Tang C, Wei J, Li M, Yuan S
Mol Med Rep. 2023; 28(2).
PMID: 37350390
PMC: 10308494.
DOI: 10.3892/mmr.2023.13036.
Yang C, Liang Y, Shu J, Wang S, Hong Y, Chen K
Int J Oncol. 2023; 62(6).
PMID: 37144499
PMC: 10198709.
DOI: 10.3892/ijo.2023.5517.
The Tumor Stemness Indice mRNAsi can Act as Molecular Typing Tool for Lung Adenocarcinoma.
Yi Y, Liu X, Gao H, Qin S, Xu J, Ma F
Biochem Genet. 2023; 61(6):2401-2424.
PMID: 37100923
DOI: 10.1007/s10528-023-10388-8.
Elevated NDC1 expression predicts poor prognosis and correlates with immunity in hepatocellular carcinoma.
Liu Q, Gu L, Qiu J, Qian J
J Gastrointest Oncol. 2023; 14(1):245-264.
PMID: 36915467
PMC: 10007937.
DOI: 10.21037/jgo-22-1166.
A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.
Zhang B, Li B, Xie Y, Chang S, Xu Z, Hu H
Acta Biochim Biophys Sin (Shanghai). 2023; 55(2):215-224.
PMID: 36815376
PMC: 10157528.
DOI: 10.3724/abbs.2023014.
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
Li S, Wang L, Wang Y, Zhang C, Hong Z, Han Z
J Hematol Oncol. 2022; 15(1):147.
PMID: 36253861
PMC: 9578258.
DOI: 10.1186/s13045-022-01360-x.
The emerging potentials of lncRNA DRAIC in human cancers.
Yao Q, Zhang X, Chen D
Front Oncol. 2022; 12:867670.
PMID: 35992823
PMC: 9386314.
DOI: 10.3389/fonc.2022.867670.
Palbociclib regulates the expression of dihydrofolate reductase and the cell cycle to inhibit t (11;14) multiple myeloma.
Wang Y, Wang H, Wang X
Ann Transl Med. 2022; 10(13):746.
PMID: 35957711
PMC: 9358508.
DOI: 10.21037/atm-22-2830.
Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivity in pancreatic cancer.
Lu S, Hua J, Xu J, Wei M, Liang C, Meng Q
Comput Struct Biotechnol J. 2022; 20:3911-3923.
PMID: 35950187
PMC: 9334218.
DOI: 10.1016/j.csbj.2022.07.029.
-Induced Progranulin Promotes the Progression of the Gastric Epithelial Cell Cycle by Regulating CDK4.
Ren Z, Li J, Du X, Shi W, Guan F, Wang X
J Microbiol Biotechnol. 2022; 32(7):844-854.
PMID: 35880418
PMC: 9628913.
DOI: 10.4014/jmb.2203.03053.
Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Quantum Leap in the Treatment of Advanced Breast Cancers.
Reddy S, Barkhane Z, Elmadi J, Kumar L, Pugalenthi L, Ahmad M
Cureus. 2022; 14(4):e23901.
PMID: 35530846
PMC: 9076043.
DOI: 10.7759/cureus.23901.
Polyphenols Extracts from Oil Production Waste Products (OPWPs) Reduce Cell Viability and Exert Anti-Inflammatory Activity via PPARγ Induction in Colorectal Cancer Cells.
Leo M, Muccillo L, Dugo L, Bernini R, Santi L, Sabatino L
Antioxidants (Basel). 2022; 11(4).
PMID: 35453308
PMC: 9029425.
DOI: 10.3390/antiox11040624.
Silibinin Therapy Improves Cholangiocarcinoma Outcomes by Regulating ERK/Mitochondrial Pathway.
Bai Y, Chen J, Hu W, Wang L, Wu Y, Yu S
Front Pharmacol. 2022; 13:847905.
PMID: 35401195
PMC: 8983842.
DOI: 10.3389/fphar.2022.847905.
Four drug metabolism-related subgroups of pancreatic adenocarcinoma in prognosis, immune infiltration, and gene mutation.
Zhang T, Zhu L, Cai J, He J
Open Med (Wars). 2022; 17(1):427-440.
PMID: 35340619
PMC: 8898926.
DOI: 10.1515/med-2022-0433.
Open Reading Frame-3a gene of the 2019 novel coronavirus inhibits the occurrence and development of colorectal cancer.
Shuwen H, Yinhang W, Jing M, Gong C, Xiaohui H, Xi Y
Discov Oncol. 2022; 13(1):14.
PMID: 35306605
PMC: 8934246.
DOI: 10.1007/s12672-022-00473-6.
Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.
Wen S, Li C, Zhan X
EPMA J. 2022; 13(1):9-37.
PMID: 35273657
PMC: 8897533.
DOI: 10.1007/s13167-022-00274-5.
DDX39B contributes to the proliferation of colorectal cancer through direct binding to CDK6/CCND1.
Zhang H, He C, Guo X, Fang Y, Lai Q, Wang X
Cell Death Discov. 2022; 8(1):30.
PMID: 35046400
PMC: 8770491.
DOI: 10.1038/s41420-022-00827-7.
